Research programme: antibacterial antibodies - Stadius Biopharma
Latest Information Update: 28 Jul 2024
At a glance
- Originator Stadius Biopharma
- Class Antituberculars; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Tuberculosis in USA (Parenteral)
- 28 Jul 2024 No recent reports of development identified for research development in Tuberculosis(Prevention) in USA (Parenteral)
- 02 Jun 2020 Early research in Tuberculosis (Prevention) in USA (Parenteral), prior to April 2020 (Stadius Biopharma pipeline, June 2020)